In this study, we demonstrate that together HDAC1 and HDAC2 activities are responsible for the decreased expression of BRCA1, CHK1, and RAD51 following class I- or pan-HDACI treatment in AML cells. Here, HDAC1 is linked to acute myeloid leukemia.